Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy
Autore:
Lacourciere, Y; Tytus, R; OKeefe, D; Lenis, J; Orchard, R; Martin, K;
Indirizzi:
Ctr Hosp Univ Quebec, Hypertens Res Unit, Quebec City, PQ G1V 4G2, Canada Ctr Hosp Univ Quebec Quebec City PQ Canada G1V 4G2 ty, PQ G1V 4G2, Canada
Titolo Testata:
JOURNAL OF HUMAN HYPERTENSION
fascicolo: 11, volume: 15, anno: 2001,
pagine: 763 - 770
SICI:
0950-9240(200111)15:11<763:EATOAF>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
TO-MODERATE HYPERTENSION; PLACEBO-CONTROLLED TRIAL; BLOOD-PRESSURE; DOUBLE-BLIND; POPULATION; ANTAGONIST; VALSARTAN; AWARENESS; COMMUNITY; THERAPY;
Keywords:
telmisartan; hydrochlorothiazide; hypertension; AT(1) receptor antagonist; fixed-dose combination therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Lacourciere, Y Ctr Hosp Univ Quebec, Hypertens Res Unit, Pavillon CHUL,2705 Blvd Laurier,Room S135, Quebec City, PQ G1V 4G2, Canada Ctr Hosp Univ Quebec Pavillon CHUL,2705 Blvd Laurier,Room S135 Quebec City PQ Canada G1V 4G2
Citazione:
Y. Lacourciere et al., "Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy", J HUM HYPER, 15(11), 2001, pp. 763-770

Abstract

The antihypertensive effects of a telmisartan 80 mg/hydrochlorothiazide (HCTZ) 12.5 mg fixed-dose combination and telmisartan 80 mg monotherapy were compared in patients with a history of mild-to-moderate essential hypertension and inadequate BP control (DBP greater than or equal to 90 mm Hg) following 8 weeks of telmisartan monotherapy. At the end of this period, 491 patients (62.9% men; mean age 55.3 years) whose DBP was greater than or equal to 90 mm Hg were double-blind randomised to once-daily telmisartan 80 mg/HCTZ 12.5 mg (n = 246) or telmisartan 80 mg (n = 245). Trough (24 h post-dose) clinic BP was measured after 4 and 8 weeks of double-blind therapy. At the end of double-blind treatment, patients receiving telmisartan 80 mg/HCTZ 12.5 mg had significant additional decrements in clinic SBP/DBP over telmisartan 80 mg of -5.7/-3.1 mmHg (P < 0.01). Most of the additional effect occurred during the first 4 weeks of treatment. The proportion of patients with normalised BP (SBP < 140 mm Hg and DBP < 90 mm Hg) was significantly greater in the telmisartan 80 mg/HCTZ 12.5 mg group than the telmisartan 80 mg group (41.5% vs 26.1%; P <0.05). Both treatments were well tolerated. The incidence of adverse events was similar except for diarrhoea, which occurredmore frequently in the telmisartan 80 mg/HCTZ 12.5 mg group, and oedema, which occurred more frequently in the telmisartan group. Our results indicate that a telmisartan 80 mg/HCTZ 12.5 mg fixed-dose combination confers significant additional BP reductions compared with continuation of telmisartan monotherapy in non-responders.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 05:05:32